Literature DB >> 15607989

Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.

L Mosconi1, K Herholz, I Prohovnik, B Nacmias, M T R De Cristofaro, M Fayyaz, L Bracco, S Sorbi, A Pupi.   

Abstract

BACKGROUND: Clinically apparent Alzheimer's disease (AD) is thought to result when brain tissue damage exceeds a critical threshold of "brain reserve", a process possibly accelerated by the apolipoprotein E (ApoE) E4 allele. The interaction between onset age and ApoE genotype was investigated to assess whether early disease onset (<65 years) in patients carrying the E4 allele is associated with greater cerebral metabolic (regional cerebral metabolic rate of glucose utilisation, rCMRgl) reduction.
METHODS: AD patients, divided into early (EOAD; 27 patients) and late onset (LOAD; 65 patients) groups, both groups balanced as to the number of E4 carriers (E4+) and non-carriers (E4-), and matched controls (NC; 35 cases) underwent (18)F-FDG PET ([(18)F]fluorodeoxyglucose positron emission tomography) scanning. SPM'99 software was used to compare AD patients to NC and to perform a two way ANOVA with onset age and ApoE genotype as grouping factors. Results were considered significant at p<0.001, uncorrected.
RESULTS: AD patients demonstrated rCMRgl reductions compared to NC, with rCMRgl lower in association cortex and relatively higher in limbic areas in EOAD compared to LOAD subjects. rCMRgl was lower in the anterior cingulate and frontal cortex for E4+ compared to E4- subjects. A significant onset age by ApoE interaction was detected in the hippocampi and basal frontal cortex, with EOAD E4+ subjects having the greatest rCMRgl reduction.
CONCLUSIONS: The interactive effects of early onset age, possibly reflecting lower brain reserve, and ApoE E4 allele, possibly leading to greater tissue damage, lead to reduced tolerance to the pathophysiological effects of AD in key brain regions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607989      PMCID: PMC1739315          DOI: 10.1136/jnnp.2003.030882

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  54 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Clinical symptoms associated with age at onset in Alzheimer's disease.

Authors:  B A Lawlor; T M Ryan; J Schmeidler; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1994-11       Impact factor: 18.112

3.  Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline.

Authors:  D Jacobs; M Sano; K Marder; K Bell; F Bylsma; G Lafleche; M Albert; J Brandt; Y Stern
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

4.  Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type.

Authors:  R Mielke; K Herholz; M Grond; J Kessler; W D Heiss
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

Review 5.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

6.  Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II).

Authors:  L Svennerholm; C G Gottfries
Journal:  J Neurochem       Date:  1994-03       Impact factor: 5.372

7.  Difference of regional cerebral metabolic pattern between presenile and senile dementia of the Alzheimer type: a factor analytic study.

Authors:  A Ichimiya; K Herholz; R Mielke; J Kessler; I Slansky; W D Heiss
Journal:  J Neurol Sci       Date:  1994-05       Impact factor: 3.181

8.  Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease.

Authors:  Y Stern; G E Alexander; I Prohovnik; R Mayeux
Journal:  Ann Neurol       Date:  1992-09       Impact factor: 10.422

9.  Intellectual decline predicts the parietal perfusion deficit in Alzheimer's disease.

Authors:  J G Keilp; I Prohovnik
Journal:  J Nucl Med       Date:  1995-08       Impact factor: 10.057

10.  Alzheimer's disease and apolipoprotein E in Italy.

Authors:  S Sorbi; B Nacmias; P Forleo; S Piacentini; L Amaducci
Journal:  Ann N Y Acad Sci       Date:  1996-01-17       Impact factor: 5.691

View more
  23 in total

Review 1.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 2.  Acute brain trauma.

Authors:  G T Martin
Journal:  Ann R Coll Surg Engl       Date:  2016-01       Impact factor: 1.891

3.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for.

Authors:  Kazunari Ishii; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

4.  Rhinal hypometabolism on FDG PET in healthy APO-E4 carriers: impact on memory function and metabolic networks.

Authors:  Mira Didic; Olivier Felician; Natalina Gour; Rafaelle Bernard; Christophe Pécheux; Olivier Mundler; Mathieu Ceccaldi; Eric Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

5.  Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes.

Authors:  Omonigho M Bubu; Elizabeth Pirraglia; Andreia G Andrade; Ram A Sharma; Sandra Gimenez-Badia; Ogie Q Umasabor-Bubu; Megan M Hogan; Amanda M Shim; Fahad Mukhtar; Nidhi Sharma; Alfred K Mbah; Azizi A Seixas; Korey Kam; Ferdinand Zizi; Amy R Borenstein; James A Mortimer; Kevin E Kip; David Morgan; Ivana Rosenzweig; Indu Ayappa; David M Rapoport; Girardin Jean-Louis; Andrew W Varga; Ricardo S Osorio
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

Review 6.  Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease.

Authors:  James M Hill; Partha S Bhattacharjee; Donna M Neumann
Journal:  Exp Eye Res       Date:  2006-09-26       Impact factor: 3.467

7.  Education and occupation provide reserve in both ApoE ε4 carrier and noncarrier patients with probable Alzheimer's disease.

Authors:  V Garibotto; B Borroni; S Sorbi; S F Cappa; A Padovani; D Perani
Journal:  Neurol Sci       Date:  2011-12-16       Impact factor: 3.307

Review 8.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 9.  Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.

Authors:  Yadong Huang; Robert W Mahley
Journal:  Neurobiol Dis       Date:  2014-08-27       Impact factor: 5.996

10.  Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.

Authors:  Jennifer L Whitwell; Jonathan Graff-Radford; Nirubol Tosakulwong; Stephen D Weigand; Mary M Machulda; Matthew L Senjem; Anthony J Spychalla; Prashanthi Vemuri; David T Jones; Daniel A Drubach; David S Knopman; Bradley F Boeve; Nilüfer Ertekin-Taner; Ronald C Petersen; Val J Lowe; Clifford R Jack; Keith A Josephs
Journal:  Alzheimers Dement       Date:  2018-03-30       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.